Why the study?
Does empagliflozin reduce cardiovascular death and heart failure hospitalization in patients with type 2 diabetes mellitus and high cardiovascular risk?
Does empagliflozin reduce cardiovascular death and heart failure hospitalization in patients with type 2 diabetes mellitus and high cardiovascular risk?
The cardiovascular benefits of empagliflozin in high-risk T2DM patients may be driven by favorable changes in cardiovascular physiology, such as reduced cardiac workload and improved ventricular arterial coupling.
Provides a physiological rationale for established SGLT2 inhibitor benefits; leaves open whether these hemodynamic mechanisms.
Cardiologists could view empagliflozin as a cardiovascular drug that also has a beneficial effect on reducing hyperglycemia in patients with type 2 diabetes mellitus (T2DM). The effects of empagliflozin in lowering the risk of cardiovascular death and hospitalization for heart failure in T2DM patients with high cardiovascular risk during the recent Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) trial may be explained principally in terms of changes to cardiovascular physiology; namely, by the potential ability of empagliflozin to reduce cardiac workload and myocardial oxygen consumption by lowering blood pressure, improving aortic compliance, and improving ventricular arterial coupling. These concepts and hypotheses are discussed in this report.
No takes yet. Share an insight, caveat, or question.
Pham et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: